The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) says that all COVID-19 enquiries are being prioritized ahead of its standard targets. It is offering an expedited advice service on coronavirus-related issues, meaning that companies wanting to make use of its other services may face some delays.
The agency says that exceptional use applications are now being processed to ensure a continued supply of non-CE marked...